A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib ...

to jump ship and share proprietary information on AbbVie’s development program for Bruton’s tyrosine kinase (BTK) degrader drugs in hematological cancers. Compared with traditional BTK ...

Nurix Therapeutics offers promising targeted protein degradation treatments for cancer and autoimmune diseases. Find out what ...

GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase BTK pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS ...

A retrospective study explored the impact of preexisting cardiovascular disease on adverse events in patients with hematologic malignancies receiving BTK inhibitors. Prevalence of CVAEs is high among ...

Inmagene LLC presented preclinical data for the novel noncovalent reversible Bruton tyrosine kinase (BTK) inhibitor IMG-004, which is in phase I development for autoimmune diseases.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

Jiangsu Vcare Pharmatech Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a Bruton’s tyrosine kinase (BTK) ...

GlobalData’s report assesses the drugs in the Protein Kinase C Beta Type pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

The company's lead candidate, NX-5948, is a Bruton's Tyrosine Kinase (BTK) degrader being developed for the treatment of B-cell malignancies and autoimmune diseases. Recent developments have ...